Pharmaceutical compositions

Abstract

A composition including a synergistic combination of a vitamin D3 or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in the prevention and/or treatment of skin photodamage, in particular in the prevention and/or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.

Description

BACKGROUND OF THE INVENTIONField of the Invention[0001]The present invention is directed towards new compositions comprising a synergistic combination of a vitamin D or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and / or treatment of inflamed skin and mucous membrane, especially in the prevention and / or treatment of skin photodamage, in particular in the prevention and / or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.Discussion of Related Art[0002]Skin disorders according to ICD-10 (International Classification of Diseases, Version 2016) include (a) group of conditions in which the skin becomes inflamed, forms blisters, and becomes crusty, thick, and scaly (including eczema causing burning and itc...

AI Technical Summary

Benefits of technology

[0011]In a first aspect, the invention is directed towards a new composition (also referred to as composition of the invention) comprising a synergistic combination of at least one vitamin D3 or a derivative or precursor thereof, preferably a precursor such as 7-DHC or a derivative thereof and at least one HA or derivative thereof, encapsulated in a lipid based colloidal carrier system (to allow for optimal skin penetration and stabilization of the vitamin D3 or a precursor or derivative thereof) and suitable formulations thereof. By encapsulation in the oil (or lipid) phase the vitamin D3 or a precursor or derivative thereof (and in particular 7-DHC or a derivative thereof) is stabilized and undesired reactions (such as oxidation or other degradation reactions) are eliminated. The lipid based colloidal carrier system allows vitamin D3 (and inactive vitamin D3 precursors such as 7-DHC or a derivative thereof) to penetrate into the upper layers of the skin, where exerts its activity (after being converted into the active vitamin D3 upon UVA and UVB exposure).

Problems solved by technology

UVB with a wavelength of 280-315 nm provides the energy the skin needs to make vitamin D3, but is also a primary mutagen that penetrates through the epidermal layer of the skin, resulting in DNA mutations, potentially leading to skin cancer (non melanoma skin cancer (NMSC) and melanoma).

UVA with a wavelength of 315-400 nm is able to penetrate deeper into the skin as compared to UVB rays and thus may damage both the epidermal and dermal layers.

With constant UVA exposure, the size of the dermis layer will be reduced, causing an atrophy of the skin.

This and other findings suggests that serum calcidiol might be associated with an increased risk of aging-related chronic diseases including cancer.

Images